glp 1 drugs and breast cancer GLP-1 use linked to lower incidence GLP-1 drugs cut breast cancer

If glucose goals are not achieved with basal insulins at doses higher than 0.5U/kg in 34months, treatment intensification should be considered

In addition to the glycemic control in T2DM, GLP-1 RAs have been demonstrated to be extraordinarily effective in the prevention and treatment of its complications [24]

These agents have been supported by important clinical trials, including Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (44)

They should not be used during pregnancy, and caution is needed in patients with history of pancreatitis, gallbladder disease, or diabetic retinopathy

Overall, treatment with semaglutide was associated with a reduction in the studys composite outcomecardiovascular death, nonfatal myocardial infarction or nonfatal strokeof 20% compared to a placebo, and it was linked to a safe and well-tolerated profile. SELECT trial results were published in the New England Journal of Medicine in November